EXEL Quote, Financials, Valuation and Earnings

Cardiff Oncology has a net margin of 24.68% compared to Exelixis's net margin of -7805.96%. Exelixis's return on equity of 23.63% beat Cardiff Oncology's return on equity of -72.03%.

Exelixis has a consensus price target of $38.05, signalling upside risk potential of 5.21%. On the other hand Cardiff Oncology has an analysts' consensus of $13.67 which suggests that it could grow by 413.79%. Given that Cardiff Oncology has higher upside potential than Exelixis, analysts believe Cardiff Oncology is more attractive than Exelixis.

Exelixis has a beta of 0.246, which suggesting that the stock is 75.352% less volatile than S&P 500. In comparison Cardiff Oncology has a beta of 1.809, suggesting its more volatile than the S&P 500 by 80.947%.

Exelixis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cardiff Oncology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exelixis pays -- of its earnings as a dividend. Cardiff Oncology pays out -- of its earnings as a dividend.

Exelixis quarterly revenues are $566.8M, which are larger than Cardiff Oncology quarterly revenues of $151K. Exelixis's net income of $139.9M is higher than Cardiff Oncology's net income of -$11.8M. Notably, Exelixis's price-to-earnings ratio is 20.44x while Cardiff Oncology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exelixis is 4.94x versus 185.29x for Cardiff Oncology. Usually stocks with elevated PS ratios are considered overvalued.

Gilead Sciences has a net margin of 24.68% compared to Exelixis's net margin of 19.72%. Exelixis's return on equity of 23.63% beat Gilead Sciences's return on equity of 32.29%.

Exelixis has a consensus price target of $38.05, signalling upside risk potential of 5.21%. On the other hand Gilead Sciences has an analysts' consensus of $115.04 which suggests that it could grow by 18.71%. Given that Gilead Sciences has higher upside potential than Exelixis, analysts believe Gilead Sciences is more attractive than Exelixis.

Exelixis has a beta of 0.246, which suggesting that the stock is 75.352% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.263, suggesting its less volatile than the S&P 500 by 73.697%.

Exelixis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 3.2% to investors and pays a quarterly dividend of $0.79 per share. Exelixis pays -- of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend.

Exelixis quarterly revenues are $566.8M, which are smaller than Gilead Sciences quarterly revenues of $6.7B. Exelixis's net income of $139.9M is lower than Gilead Sciences's net income of $1.3B. Notably, Exelixis's price-to-earnings ratio is 20.44x while Gilead Sciences's PE ratio is 20.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exelixis is 4.94x versus 4.25x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of 24.68% compared to Exelixis's net margin of --. Exelixis's return on equity of 23.63% beat Viking Therapeutics's return on equity of --.

Exelixis has a consensus price target of $38.05, signalling upside risk potential of 5.21%. On the other hand Viking Therapeutics has an analysts' consensus of $90.26 which suggests that it could grow by 227.63%. Given that Viking Therapeutics has higher upside potential than Exelixis, analysts believe Viking Therapeutics is more attractive than Exelixis.

Exelixis has a beta of 0.246, which suggesting that the stock is 75.352% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.754, suggesting its less volatile than the S&P 500 by 24.558%.

Exelixis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exelixis pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

Exelixis quarterly revenues are $566.8M, which are larger than Viking Therapeutics quarterly revenues of --. Exelixis's net income of $139.9M is higher than Viking Therapeutics's net income of -$45.6M. Notably, Exelixis's price-to-earnings ratio is 20.44x while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exelixis is 4.94x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Verastem has a net margin of 24.68% compared to Exelixis's net margin of -82.56%. Exelixis's return on equity of 23.63% beat Verastem's return on equity of -120.71%.

Exelixis has a consensus price target of $38.05, signalling upside risk potential of 5.21%. On the other hand Verastem has an analysts' consensus of $15.75 which suggests that it could grow by 112.69%. Given that Verastem has higher upside potential than Exelixis, analysts believe Verastem is more attractive than Exelixis.

Exelixis has a beta of 0.246, which suggesting that the stock is 75.352% less volatile than S&P 500. In comparison Verastem has a beta of 0.855, suggesting its less volatile than the S&P 500 by 14.503%.

Exelixis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verastem offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exelixis pays -- of its earnings as a dividend. Verastem pays out -- of its earnings as a dividend.

Exelixis quarterly revenues are $566.8M, which are larger than Verastem quarterly revenues of $10M. Exelixis's net income of $139.9M is higher than Verastem's net income of -$64.6M. Notably, Exelixis's price-to-earnings ratio is 20.44x while Verastem's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exelixis is 4.94x versus -- for Verastem. Usually stocks with elevated PS ratios are considered overvalued.